Cue Biopharma ( (CUE) ) has released its Q2 earnings. Here is a breakdown of the information Cue Biopharma presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cue Biopharma, Inc., based in Boston, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing innovative biologics to selectively engage and modulate disease-specific T cells for treating autoimmune diseases and cancer. The company’s proprietary Immuno-STAT® platform aims to harness the immune system’s potential without adverse systemic effects.
In its second quarter of 2025 financial report, Cue Biopharma highlighted significant progress, including FDA feedback on its CUE-401 program and a strategic collaboration with Boehringer Ingelheim. The company also raised $20 million through a public offering, bolstering its financial position.
Key financial metrics for the quarter included collaboration revenue of $3.0 million, an increase from the previous year, and a decrease in research and development expenses to $7.9 million. The company reported a net loss of $8.5 million, reflecting ongoing investments in its clinical programs.
Strategically, Cue Biopharma’s collaboration with Boehringer Ingelheim for CUE-501, a B cell depletion therapy, marks a significant milestone, with potential milestone payments of up to $345 million. Additionally, the company reported promising clinical data from its CUE-101 program, showing a 50% overall response rate in a Phase 1 trial for HPV+ head and neck cancer.
Looking ahead, Cue Biopharma remains committed to advancing its pipeline and leveraging strategic partnerships to address unmet medical needs in autoimmune diseases and cancer, with a focus on achieving regulatory milestones and expanding its therapeutic offerings.